Modulating carbohydrate-protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current Opinion in Structural Biology

• Publication date

  2016-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.sbi.2016.08.008PMID 27639240PMCID PMC5161599
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Markov chain model for N-linked protein glycosylation--towards a low-parameter tool for model-driven glycoengineering.

  2016cited by this paper
• N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies.

  2016cited by this paper
• Transcriptome study and identification of potential marker genes related to the stable expression of recombinant proteins in CHO clones

  2015cited by this paper
• Insights into the Impact of Heterogeneous Glycosylation on the Pharmacokinetic Behavior of Follistatin-Fc–Based Biotherapeutics

  2015cited by this paper
• Optimizing eukaryotic cell hosts for protein production through systems biotechnology and genome‐scale modeling

  2015cited by this paper
• Glyco-Engineering. Preface.

  2015cited by this paper
• Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.

  2015cited by this paper
• The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis

  2015cited by this paper
• The Structural Role of Antibody N-Glycosylation in Receptor Interactions.

  2015cited by this paper
• Glyco-Engineering

  2015cited by this paper
• Fc glycans of therapeutic antibodies as critical quality attributes

  2015cited by this paper
• A common glycan structure on immunoglobulin G for enhancement of effector functions

  2015cited by this paper
• A global RNA-seq-driven analysis of CHO host and production cell lines reveals distinct differential expression patterns of genes contributing to recombinant antibody glycosylation.

  2015cited by this paper
• Amino acid and glucose metabolism in fed‐batch CHO cell culture affects antibody production and glycosylation

  2015cited by this paper
• Chapter 2 : Fc glycans of therapeutic antibodies as critical quality attributes ( CQAs )

  2015cited by this paper
• Obinutuzumab in hematologic malignancies: lessons learned to date.

  2015influential reference
• Toward genome-scale models of the Chinese hamster ovary cells: incentives, status and perspectives

  2014cited by this paper
• Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro

  2014cited by this paper
• GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins

  2014cited by this paper
• Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.

  2014cited by this paper
• Glycosylation and Fc receptors.

  2014cited by this paper
• Biopharmaceutical benchmarks 2014

  2014influential reference
• Model based engineering of Pichia pastoris central metabolism enhances recombinant protein production

  2014cited by this paper
• Influence of glycosylation pattern on the molecular properties of monoclonal antibodies

  2014cited by this paper
• Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells

  2014cited by this paper
• Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity

  2014cited by this paper
• The emerging CHO systems biology era: harnessing the 'omics revolution for biotechnology.

  2013cited by this paper
• Integration of the Transcriptome and Glycome for Identification of Glycan Cell Signatures

  2013cited by this paper
• VEGF targets the tumour cell

  2013cited by this paper
• Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications

  2013cited by this paper
• The evolution of genome-scale models of cancer metabolism

  2013cited by this paper
• Antibody therapy of cancer

  2012cited by this paper
• Marketing approval of mogamulizumab

  2012cited by this paper
• The impact of glycosylation on monoclonal antibody conformation and stability

  2011cited by this paper
• Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

  2011influential reference
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose

  2011influential reference
• [Antibody therapy in cancer].

  2010cited by this paper
• Glycosylation of Therapeutic Proteins

  2010cited by this paper
• The safety and side effects of monoclonal antibodies

  2010cited by this paper
• Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma

  2010cited by this paper
• Large-scale in silico modeling of metabolic interactions between cell types in the human brain

  2010cited by this paper
• GlycomeDB—a unified database for carbohydrate structures

  2010cited by this paper
• Glycosylation as a strategy to improve antibody-based therapeutics

  2009cited by this paper
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008cited by this paper
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008cited by this paper
• Complement as effector system in cancer immunotherapy.

  2007cited by this paper
• Fc Glycans Terminated with N‐Acetylglucosamine Residues Increase Antibody Resistance to Papain

  2007cited by this paper
• Siglecs and their roles in the immune system

  2007cited by this paper
• Potent antibody therapeutics by design

  2006cited by this paper
• Establishing risk of human experimentation with drugs: lessons from TGN1412.

  2006cited by this paper
• Engineering cells for cell culture bioprocessing--physiological fundamentals.

  2006cited by this paper
• Selecting and screening recombinant antibody libraries

  2005cited by this paper
• Controlled glycosylation of therapeutic antibodies in plants.

  2004cited by this paper
• Structural and functional analysis of the costimulatory receptor programmed death-1.

  2004cited by this paper
• Enhancement of therapeutic protein in vivo activities through glycoengineering

  2003cited by this paper
• Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.

  2003cited by this paper
• Biopharmaceutical benchmarks

  2000cited by this paper
• 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.

  1999cited by this paper
• Fc receptors are required in passive and active immunity to melanoma.

  1998influential reference
• The PMT gene family: protein O‐glycosylation in Saccharomyces cerevisiae is vital.

  1996cited by this paper
• The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H.

  1995cited by this paper
• Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure.

  1991cited by this paper

• A Computational and Chemical Design Strategy for Manipulating Glycan‐Protein Recognition

  2024cites this paper
• Modulating antibody effector functions by Fc glycoengineering.

  2023cites this paper
• Site-Specific Antibody Conjugation Using Modified Bisected N-Glycans: Method Development and Potential toward Tunable Effector Function

  2023cites this paper
• Enhanced antibody-defucosylation capability of α-L-fucosidase by proximity-based protein fusion.

  2023cites this paper
• Biomanufacturing of glycosylated antibodies: Challenges, solutions, and future prospects.

  2023cites this paper
• Investigating a Boronate-Affinity Guided Acylation Reaction for Labelling Native Antibodies.

  2022cites this paper
• Monoclonal Antibody Glycoengineering for Biopharmaceutical Quality Assurance

  2021cites this paper
• Successive remodeling of IgG glycans using a solid-phase enzymatic platform

  2021cites this paper
• Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors

  2021cites this paper
• Molecular and Mechanistic Basis of Lectin-Glycan Interactions

  2020cites this paper
• Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid

  2020cites this paper
• A Markov model of glycosylation elucidates isozyme specificity and glycosyltransferase interactions for glycoengineering.

  2020cites this paper
• Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering.

  2020cites this paper
• IgE Antibodies against Cancer: Efficacy and Safety

  2020influential citation
• Awakening dormant glycosyltransferases in CHO cells with CRISPRa

  2019cites this paper
• IDENTIFICATION & COMPARISON OF HAEMATOLOGICAL INDICES & CLINICAL CORRELATES OF FLT3 MUTATION IN AML AND ALL

  2019cites this paper
• Harnessing the power of an expanded genetic code toward next-generation biopharmaceuticals.

  2018cites this paper
• The emerging role of systems biology for engineering protein production in CHO cells.

  2018cites this paper
• Glycans and glycosaminoglycans in neurobiology: key regulators of neuronal cell function and fate.

  2018cites this paper
• Predictive glycoengineering of biosimilars using a Markov chain glycosylation model.

  2017cites this paper
• Improvements in protein production in mammalian cells from targeted metabolic engineering.

  2017cites this paper
• Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development

  2017cites this paper